Intelligence Platform

Patents

Browse 405 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11464856

Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15

Julius-Maximilians-Universitat Wurzburg · Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11464774

Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

Vertex Pharmaceuticals Incorporated · Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11458127

Methods of treating brain tumors using combination therapy

Agios Pharmaceuticals, Inc. · Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11452723

Combination dosage form of a mu opioid receptor antagonist and an opioid agent

Theravance Biopharma R&D IP, LLC · Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11440963

Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11426379

Combination of local and systemic therapies for enhanced treatment of dermatologic conditi

Provectus Pharmatech, Inc. · Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11421034

Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

Five Prime Therapeutics, Inc. · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11414489

Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor

HALOZYME, INC. · Granted Tue Aug 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11400123

Combination product for prophylaxis and treatment of irritable bowel syndrome

PrecisionBiotics Group Limited · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11397184

Selection of patients for combination therapy

Syndax Pharmaceuticals, Inc. · Granted Tue Jul 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11382897

Therapeutic combination for treatment of cerebellar ataxia

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11365265

Anti-C5 antibody combinations and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11357795

Combination immunotherapies for treatment of cancer

PrimeVax Immuno-Oncology · Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11351153

Antimicrobial compositions containing a synergistic combination of activated creatinine an

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11338013

Combination therapy for C3 inhibition

Apellis Pharmaceuticals, Inc. · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11331370

Combination product for the prevention of sexually transmitted infections

The United States of America · Granted Tue May 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11324822

Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

Syndax Pharmaceuticals, Inc. · Granted Tue May 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11318164

Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist

Nektar Therapeutics · Granted Tue May 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11311517

Combination of small molecule CD-47 inhibitors with other anti-cancer agents

Aurigene Discovery Technologies Limited · Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11311581

Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceuticall

AGAIN LIFE ITALIA SRL · Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11311574

Methods and compositions for targeted cleavage and recombination

Sangamo Therapeutics, Inc. · Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11291667

Combination therapy involving diaryl macrocyclic compounds

TURNING POINT THERAPEUTICS, INC. · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11285194

Combination immunotherapy approach for treatment of cancer

Calidi Biotherapeutics, Inc. · Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11279768

Anti-cancer antibodies, combination therapies, and uses thereof

PRECISION BIOLOGICS, INC. · Granted Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted